Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 + Serplulimab +/- Platinum in Advanced Solid Tumors
NCT06394414Phase 1Active, not recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of YL201 in solid tumor (advanced stage) (2 arms), sponsored by MediLink Therapeutics. Primary endpoints: Adverse Events at 36 months, Maximum Tolerated Dose / Recommended Expansion Dose at 36 months and 2 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
YL201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06394414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394414.